Posted by Michael Wonder on 30 Sep 2016
Recommendations made by the PBAC - August 2016
30 September 2016 - The outcomes from the August 2016 PBAC meeting are now available.
The PBAC met in August to consider the reimbursement of:
- Idelalisib
- Sacubitril with valsartan
- Influenza vaccine (quadrivalent)
- Ibrutunib
While the PBAC has recommended the listing of idelalisib for a new patient populations (patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) with a certain genetic mutation), it once again rejected the listing of ibrutinib for patients with CLL or SLL without a genetic mutation.
